<code id='0761FA089D'></code><style id='0761FA089D'></style>
    • <acronym id='0761FA089D'></acronym>
      <center id='0761FA089D'><center id='0761FA089D'><tfoot id='0761FA089D'></tfoot></center><abbr id='0761FA089D'><dir id='0761FA089D'><tfoot id='0761FA089D'></tfoot><noframes id='0761FA089D'>

    • <optgroup id='0761FA089D'><strike id='0761FA089D'><sup id='0761FA089D'></sup></strike><code id='0761FA089D'></code></optgroup>
        1. <b id='0761FA089D'><label id='0761FA089D'><select id='0761FA089D'><dt id='0761FA089D'><span id='0761FA089D'></span></dt></select></label></b><u id='0761FA089D'></u>
          <i id='0761FA089D'><strike id='0761FA089D'><tt id='0761FA089D'><pre id='0761FA089D'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:hotspot    Page View:1
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In